Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Paclitaxel
Drug ID BADD_D01653
Description Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Indications and Usage Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
Marketing Status approved; vet_approved
ATC Code L01CD01
DrugBank ID DB01229
KEGG ID D00491
MeSH ID D017239
PubChem ID 36314
TTD Drug ID D0C4RB
NDC Product Code 0703-3213; 52222-0001; 65129-1308; 68083-179; 69539-159; 62422-0004; 68001-516; 68083-178; 0703-4768; 68554-0061; 46708-622; 47781-595; 62332-621; 62332-622; 63323-763; 72205-063; 60505-6230; 62332-620; 72205-062; 0517-4300; 0703-3216; 0703-3218; 17359-3055; 63126-902; 69539-158; 72205-061; 17359-4056; 49452-4961; 51446-0110; 59651-605; 0703-4764; 51446-0120; 46708-620; 61703-342; 68083-180; 0703-3217; 17359-4040; 62422-0002; 69539-157; 70860-215; 42533-111; 54893-0007; 65129-2039; 69443-022; 16714-137; 68817-134; 70860-200; 17359-4055; 65892-002; 24979-710; 46708-621
UNII P88XT4IS4D
Synonyms Paclitaxel | Anzatax | NSC-125973 | NSC 125973 | NSC125973 | Taxol | Taxol A | Bris Taxol | Taxol, Bris | Paclitaxel, (4 alpha)-Isomer | Paxene | Praxel | 7-epi-Taxol | 7 epi Taxol | Onxol
Chemical Information
Molecular Formula C47H51NO14
CAS Registry Number 33069-62-4
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6) O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lymphopenia01.02.02.0020.000750%Not Available
Macular degeneration06.09.03.0010.000112%Not Available
Macular oedema06.04.06.0050.001757%Not Available
Maculopathy06.09.03.0070.000392%Not Available
Malaise08.01.01.0030.009503%
Mass08.03.05.0030.000224%Not Available
Melaena24.07.02.013; 07.12.02.004--Not Available
Meningitis cryptococcal17.06.04.001; 11.03.04.002--Not Available
Menopausal symptoms21.02.02.002--Not Available
Mental disability26.01.01.001--Not Available
Metastases to liver09.04.02.004; 16.22.02.0010.001030%Not Available
Metastases to lung22.08.01.005; 16.22.02.0020.000504%Not Available
Micturition urgency20.02.02.0060.000224%
Mood altered19.04.02.007--Not Available
Mood swings19.04.03.001--Not Available
Morphoea23.03.02.011; 15.06.01.008; 10.04.07.002--Not Available
Mouth ulceration07.05.06.004--Not Available
Movement disorder17.01.02.010--Not Available
Mucosal dryness08.01.06.0010.000168%Not Available
Mucosal inflammation08.01.06.0020.002518%Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Musculoskeletal pain15.03.04.0070.000672%
Myalgia15.05.02.0010.003089%
Myasthenia gravis17.05.04.001; 15.05.08.001; 10.04.05.0010.000112%
Mydriasis17.02.11.003; 06.05.03.0040.000336%Not Available
Myelodysplastic syndrome01.10.04.001; 16.01.04.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia24.04.04.010; 02.02.02.0080.000224%Not Available
Myositis15.05.01.0010.000224%
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene